NCT05800366 2026-03-05A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell LymphomaDana-Farber Cancer InstitutePhase 2 Recruiting41 enrolled
NCT06624085 2026-03-04A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaHoffmann-La RochePhase 1 Recruiting50 enrolled